RÉSUMÉ
Malva parviflora has shown anti-inflammatory, antihypertensive, antihyperlipidemic, and hypoglycemic effects. This study is aimed to evaluate the anti-adipogenic effect of M. parviflora on 3T3-L1 adipocytes. Fibroblast differentiation was induced either in the absence or presence of M. parviflora fractions (F3, F4, F7, F12, F13, F17, F18 and F19) for 4 days; F17 and 18 were the most effective fractions in reducing intracellular lipid accumulation (by 25.6% and 23.1%, respectively). EC50 of F17 and F18 (14 µg/mL and 17 µg/mL, respectively) were used to evaluate their anti adipogenic effect. After 10 days of inducing differentiation in the absence or presence of the extracts at the EC50 of F17 and F18, lipid accumulation, the concentration of interleukin 6 (IL-6) were measured in the culture medium; the presence of PPAR-γ, AKT, and p-AKT was also determined. In differentiated adipocytes (C2), F17 maintained intracellular lipid concentration at levels comparable to metformin, while decreasing PPAR-γ and increasing p-AKT presence; it also prevented IL-6 expression. F17 consists of alanine, valine, phenylalanine, and proline. On the other hand, F18 reduced intracellular lipid concentrations, prevented the increase of PPAR-γ and p-AKT, and maintained IL-6 expression at similar levels as metformin. F18 is mainly constituted by alanine, valine, proline, and sucrose. In conclusion, M. parviflora fractions (F17 and F18) control the process of adipogenesis, lipogenesis, and cellular dysfunction.
Sujet(s)
Cellules 3T3-L1 , Adipocytes , Adipogenèse , Récepteur PPAR gamma , Extraits de plantes , Animaux , Souris , Adipocytes/effets des médicaments et des substances chimiques , Adipocytes/métabolisme , Adipocytes/cytologie , Adipogenèse/effets des médicaments et des substances chimiques , Extraits de plantes/pharmacologie , Récepteur PPAR gamma/métabolisme , Interleukine-6/métabolisme , Différenciation cellulaire/effets des médicaments et des substances chimiques , Métabolisme lipidique/effets des médicaments et des substances chimiques , Protéines proto-oncogènes c-akt/métabolismeRÉSUMÉ
White adipocytes store energy, while brown and brite adipocytes release heat via nonshivering thermogenesis. In this study, we characterized two murine embryonic clonal preadipocyte lines, EB5 and EB7, each displaying unique gene marker expression profiles. EB5 cells differentiate into brown adipocytes, whereas EB7 cells into brite (also known as beige) adipocytes. To draw a comprehensive comparison, we contrasted the gene expression patterns, adipogenic capacity, as well as carbohydrate and lipid metabolism of these cells to that of F442A, a well-known white preadipocyte and adipocyte model. We found that commitment to differentiation in both EB5 and EB7 cells can be induced by 3-Isobutyl-1-methylxanthine/dexamethasone (Mix/Dex) and staurosporine/dexamethasone (St/Dex) treatments. Additionally, the administration of rosiglitazone significantly enhances the brown and brite adipocyte phenotypes. Our data also reveal the involvement of a series of genes in the transcriptional cascade guiding adipogenesis, pinpointing GSK3ß as a critical regulator for both EB5 and EB7 adipogenesis. In a developmental context, we observe that, akin to brown fat progenitors, brite fat progenitors make their appearance in murine development by 11-12 days of gestation or potentially earlier. This result contributes to our understanding of adipocyte lineage specification during embryonic development. In conclusion, EB5 and EB7 cell lines are valuable for research into adipocyte biology, providing insights into the differentiation and development of brown and beige adipocytes. Furthermore, they could be useful for the characterization of drugs targeting energy balance for the treatment of obesity and metabolic diseases.
Sujet(s)
Adipocytes beiges , Adipocytes bruns , Adipogenèse , Différenciation cellulaire , Animaux , Souris , Adipocytes bruns/métabolisme , Adipocytes bruns/cytologie , Adipocytes bruns/effets des médicaments et des substances chimiques , Adipocytes beiges/métabolisme , Adipocytes beiges/cytologie , Adipogenèse/génétique , Adipogenèse/effets des médicaments et des substances chimiques , Différenciation cellulaire/génétique , Différenciation cellulaire/effets des médicaments et des substances chimiques , Lignée cellulaireRÉSUMÉ
The study evaluated the effects of Arthrospira maxima phycobiliproteins (PBPs), rosiglitazone (RSG), and 17ß-estradiol (E) on the differentiation process of 3T3-L1 cells and on their regulation of lipogenic and inflammatory gene expression at different stages of the process. The results showed that phycobiliproteins promoted cell proliferation after 24 h of treatment. Furthermore, for all three treatments, the regulation of the highest number of markers occurred on days 6 and 12 of differentiation, regardless of when the treatment was applied. Phycobiliproteins reduced lipid droplet accumulation on days 3, 6, 10, and 13 of the adipogenic process, while rosiglitazone showed no differences compared to the control. On day 6, both phycobiliproteins and rosiglitazone positively regulated Acc1 mRNA. Meanwhile, all three treatments negatively regulated Pparγ and C/ebpα. Phycobiliproteins and estradiol also negatively regulated Ucp1 and Glut4 mRNAs. Rosiglitazone and estradiol, on the other hand, negatively regulated Ppara and Il-6 mRNAs. By day 12, phycobiliproteins and rosiglitazone upregulated Pparγ mRNA and negatively regulated Tnfα and Il-1ß. Additionally, phycobiliproteins and estradiol positively regulated Il-6 and negatively regulated Ppara, Ucp2, Acc1, and Glut4. Rosiglitazone and estradiol upregulate C/ebpα and Ucp1 mRNAs. The regulation exerted by phycobiliproteins on the mRNA expression of the studied markers was dependent on the phase of cell differentiation. The results of this study highlight that phycobiliproteins have an anti-adipogenic and anti-inflammatory effect by reducing the expression of adipogenic, lipogenic, and inflammatory genes in 3T3-L1 cells at different stages of the differentiation process.
Sujet(s)
Cellules 3T3-L1 , Adipocytes , Adipogenèse , Différenciation cellulaire , Oestradiol , Phycobiliprotéines , Rosiglitazone , Animaux , Souris , Oestradiol/pharmacologie , Rosiglitazone/pharmacologie , Adipocytes/effets des médicaments et des substances chimiques , Adipocytes/métabolisme , Adipocytes/cytologie , Différenciation cellulaire/effets des médicaments et des substances chimiques , Adipogenèse/effets des médicaments et des substances chimiques , Adipogenèse/génétique , Phycobiliprotéines/pharmacologie , Phycobiliprotéines/métabolisme , Phycobiliprotéines/génétique , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Lipogenèse/effets des médicaments et des substances chimiques , Lipogenèse/génétique , Récepteur PPAR gamma/métabolisme , Récepteur PPAR gamma/génétique , Prolifération cellulaire/effets des médicaments et des substances chimiques , Inflammation/métabolisme , Inflammation/génétique , SpirulinaRÉSUMÉ
Osteoporosis is the most common metabolic bone disorder and is associated with a high incidence of fractures. Angiogenesis and adequate blood flow are important during bone repair and maintenance. Estrogens play a key role in bone formation, in the prevention of bone resorption and vasculature maintenance. Hormone replacement therapy (HRT) has been used with great benefits for bone fracture prevention but has been linked to the development of serious important side effects, including cancer and stroke. Phytoestrogens are an attractive alternative to HRT because their chemical structure is similar to estradiol but, they could behave as selective modulators: acting as antagonists of estrogen receptors in the breast and endometrium and as agonists in the vascular endothelium and bone. Hops contain a wide variety of phytoestrogens that have individually been shown to possess estrogenic activity by either blocking or mimicking. In this study we have to evaluate the in vitro effects and mechanisms of action of hops extracts on the osteogenic and adipogenic capacity of bone marrow progenitor cells (BMPCs), and the angiogenic potential of EA.hy926 endothelial cells. We show that hops extracts increase the proliferative capacity of BMPCs and promote their osteogenic differentiation while decreasing their pro-osteoclastogenic capacity; and that these effects are mediated by the MAPK pathway. Additionally, hops extracts prevent the adipogenic differentiation of BMPCs and promote endothelial cell activity, by mechanisms also partially mediated by MAPK.
Sujet(s)
Cellules de la moelle osseuse , Différenciation cellulaire , Prolifération cellulaire , Cellules endothéliales , Humulus , Ostéogenèse , Extraits de plantes , Humulus/composition chimique , Ostéogenèse/effets des médicaments et des substances chimiques , Humains , Cellules endothéliales/effets des médicaments et des substances chimiques , Cellules endothéliales/métabolisme , Extraits de plantes/pharmacologie , Prolifération cellulaire/effets des médicaments et des substances chimiques , Différenciation cellulaire/effets des médicaments et des substances chimiques , Animaux , Cellules de la moelle osseuse/effets des médicaments et des substances chimiques , Cellules de la moelle osseuse/métabolisme , Cellules de la moelle osseuse/cytologie , Cellules souches/effets des médicaments et des substances chimiques , Cellules souches/métabolisme , Cellules souches/cytologie , Néovascularisation physiologique/effets des médicaments et des substances chimiques , Phyto-oestrogènes/pharmacologie , Adipogenèse/effets des médicaments et des substances chimiques , Souris , Système de signalisation des MAP kinases/effets des médicaments et des substances chimiques , Cellules cultivées , Lignée cellulaireRÉSUMÉ
Periodontal ligament stem cells (PDLSCs) show plasticity towards the adipogenic lineage; however, little has been done on the participation of epigenetic mechanisms. Histone acetylation is a dynamic process, though balanced by histone acetyltransferases (HATs) and histone deacetylases (HDACs) activities. This process can be halted by HDACs inhibitors, such as trichostatin A (TSA) and valproic acid (VPA). This study aimed to determine the role of HDACs class I in adipogenic differentiation of PDL cells. PDLSCs were treated with TSA at concentrations of 100, 200, and 250 nM, or VPA at 1, 4 and 8 mM. Cell viability was assessed using MTT assays. Gene expression of pluripotency markers (NANOG, OCT4, SOX2), HAT genes (p300, GCN5), and HDACs genes (HDAC1-3) was analyzed by RT-qPCR. Adipogenic differentiation was evaluated via oil red O staining, and acetylation of histone H3 lysine 9 (H3K9ac) was examined by Western blot. VPA treatment resulted in a 60% reduction in cell proliferation, compared to a 50% when using TSA. Cell viability was not affected by either inhibitor. Furthermore, both TSA and VPA induced adipogenic differentiation, through an increase in the deposition of lipid droplets and in GCN5 and p300 expression were observed. Western blot analysis showed that TSA increased H3K9ac levels on adipogenic differentiation of PDLSCs. These findings highlight the potential of HDAC inhibitors as a tool for modulating H3K9 acetylation status and thus influencing adipogenic differentiation of PDLCs.
Sujet(s)
Adipogenèse , Différenciation cellulaire , Survie cellulaire , Inhibiteurs de désacétylase d'histone , Desmodonte , Acide valproïque , Humains , Desmodonte/cytologie , Desmodonte/effets des médicaments et des substances chimiques , Inhibiteurs de désacétylase d'histone/pharmacologie , Adipogenèse/effets des médicaments et des substances chimiques , Adipogenèse/génétique , Acide valproïque/pharmacologie , Différenciation cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques , Acétylation/effets des médicaments et des substances chimiques , Histone deacetylases/métabolisme , Histone deacetylases/génétique , Acides hydroxamiques/pharmacologie , Cellules cultivées , Histone/métabolisme , Prolifération cellulaire/effets des médicaments et des substances chimiques , Cellules souches/effets des médicaments et des substances chimiques , Cellules souches/cytologie , Cellules souches/métabolismeRÉSUMÉ
Telmisartan (TELM) is an angiotensin II (Ang II) type 1 receptor (Agtr1) antagonist, with partial agonism for Pparg, and has been shown to affect bone metabolism. Therefore, the aim of this study was to investigate the effects of TELM in the in vitro osteogenic differentiation of bone marrow-derived mesenchymal stromal cells (BMSC) from spontaneously hypertensive rats (SHRs). BMSC were obtained from male SHR, and the osteogenic medium (OM) was added to the cells concomitantly with TELM (0.005, 0.05, and 0.5 µM). Undifferentiated BMSC, in control medium (CM), showed an increased viability, while the addition of OM reduced this parameter, and TELM did not show cytotoxicity in the concentrations used. BMSC in OM had an alkaline phosphatase (ALP) activity peak at d10, which decreased at d14 and d21, and TELM reduced ALP at d10 in a dose-dependent manner. Mineralization was observed in the OM at d14, which intensified at d21, but was inhibited by TELM. Agtr1b was increased in the OM, and TELM inhibited its expression. TELM reduced Opn, Ocn, and Bsp and increased Pparg expression, and at the higher concentration TELM also increased the expression of adipogenic markers, Fabp4 and Adipoq. In addition, TELM 0.5 µM increased Irs1 and Glut4, insulin and glucose metabolism markers, known to be regulated by Pparg and to be related to adipogenic phenotype. Our data shows that TELM inhibited the osteogenic differentiation and mineralization of SHR BMSC, by favoring an adipogenic prone phenotype due to Pparg upregulation.
Sujet(s)
Différenciation cellulaire/effets des médicaments et des substances chimiques , Cellules souches mésenchymateuses/effets des médicaments et des substances chimiques , Ostéogenèse/effets des médicaments et des substances chimiques , Telmisartan/pharmacologie , Adipogenèse/effets des médicaments et des substances chimiques , Adipogenèse/génétique , Phosphatase alcaline/métabolisme , Animaux , Calcification physiologique/effets des médicaments et des substances chimiques , Matrice extracellulaire/métabolisme , Mâle , Récepteur PPAR gamma/métabolisme , Rats de lignée SHR , Récepteurs aux angiotensines/génétique , Récepteurs aux angiotensines/métabolismeRÉSUMÉ
AIM: An adverse endogenous environment during early life predisposes to metabolic disorder development. We previously reported adverse metabolic and adipose tissue effects in adult male rats born to dams fed with a fructose-rich diet (FRD). The aim of this work was to determine the effect of a FRD consumed by the pregnant mother on the white adipose tissue (WAT) browning capacity of male offspring at adulthood. MAIN METHODS: Adult SD male offspring from control (C) and FRD-fed mothers were exposed during one week to a cold stimulus. WAT browning capacity was studied through in vivo and in vitro approaches. KEY FINDINGS: After cold exposure, WAT browning was higher in fructose-programmed animals as evidenced by an increase in ucp-1 gene expression, protein levels, and higher UCP-1 positive foci. Moreover, pgc1-α gene expression was increased. In vitro studies showed a lower adipogenic capacity in cells of prenatally fructose-exposed animals differentiated with a white differentiation cocktail, while a higher ucp-1 expression was noted when their cells were treated with a pro-beige differentiation cocktail. SIGNIFICANCE: For the first time we demonstrate that pre-natal fructose exposure predisposes programmed male rats to a higher WAT browning-induced response, under stimulated conditions, despite an apparent lower basal thermogenic capacity. These results should be considered in future studies to generate new therapeutic approaches to deal with adverse programming malnutrition effects.
Sujet(s)
Tissu adipeux blanc/métabolisme , Basse température/effets indésirables , Sucres alimentaires/toxicité , Fructose/toxicité , Effets différés de l'exposition prénatale à des facteurs de risque/métabolisme , Thermogenèse/physiologie , Adipogenèse/effets des médicaments et des substances chimiques , Adipogenèse/physiologie , Tissu adipeux blanc/effets des médicaments et des substances chimiques , Animaux , Sucres alimentaires/administration et posologie , Métabolisme énergétique/effets des médicaments et des substances chimiques , Métabolisme énergétique/physiologie , Femelle , Fructose/administration et posologie , Mâle , Grossesse , Effets différés de l'exposition prénatale à des facteurs de risque/induit chimiquement , Rats , Rat Sprague-Dawley , Thermogenèse/effets des médicaments et des substances chimiquesRÉSUMÉ
Bismuth-based nanoparticles (BiNPs) have attracted attention for their potential biomedical applications. However, there is a lack of information concerning their interaction with biological systems. In this study, it was investigated the effect of physically synthesized BiNPs to human adipose-derived stem cells (ADSCs). We first evaluated the influence of BiNPs on cell viability, cell morphology, mitochondrial function and cell proliferation. Further, the impact of BiNPs on adipogenic differentiation was also explored. Cytotoxicity assays have demonstrated that BiNPs did not reduce relative cell viability of ADSC except at the highest tested concentration (345 µg/ml). Analysis of cell morphology performed by transmission electron microscopy confirmed that BiNPs induced cell damage only at a high concentration (302.24 µg/ml), equivalent to IC50 concentration. Moreover, BiNPs exposure increased the expression of the cell proliferation marker Ki-67 and the incorporation of the thymidine analogue EdU into cell DNA, suggesting that these nanoparticles could be stimulating ADSC proliferation. BiNPs also increased the mitochondrial membrane potential. Furthermore, BiNPs reduced ADSC adipogenic differentiation as measured by lipid droplet accumulation and mRNA expression levels of the specific adipogenesis biomarkers PPARγ, C/EPBÉ and FABP4. Thus, BiNPs affect the nonspecific (viability, proliferation and mitochondrial activity) and specific (adipogenesis) cellular mechanisms of ADSCs.
Sujet(s)
Adipogenèse/effets des médicaments et des substances chimiques , Bismuth/toxicité , Différenciation cellulaire/effets des médicaments et des substances chimiques , Cellules souches mésenchymateuses/effets des médicaments et des substances chimiques , Nanoparticules métalliques/toxicité , Prolifération cellulaire/effets des médicaments et des substances chimiques , Survie cellulaire/effets des médicaments et des substances chimiques , Relation dose-effet des médicaments , Humains , Potentiel de membrane mitochondriale/effets des médicaments et des substances chimiquesRÉSUMÉ
Inhibition of adipocyte differentiation can be used as a strategy for preventing adipose tissue expansion and, consequently, for obesity management. Since reactive oxygen species (ROS) have emerged as key modulators of adipogenesis, the effect of menadione (a synthetic form of vitamin K known to induce the increase of intracellular ROS) on 3T3-L1 preadipocyte differentiation was studied. Menadione (15 µM) increased ROS and lipid peroxidation, generating mild oxidative stress without affecting cell viability. Menadione drastically inhibited adipogenesis, accompanied by decreased intracellular lipid accumulation and diminished expression of the lipo/adipogenic markers peroxisome proliferator-activated receptor (PPAR)γ, fatty acid synthase (FAS), CCAAT/enhancer-binding protein (C/EBP) α, fatty acid binding protein (FABP) 4, and perilipin. Menadione treatment also increased lipolysis, as indicated by augmented glycerol release and reinforced by the increased expression of hormone-sensitive lipase (HSL). Additionally, menadione increased the inhibitory phosphorylation of acetyl-CoA-carboxylase (ACC), which results in the inhibition of fatty acid synthesis. As a consequence, triglyceride content was decreased. Menadione also inhibited the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Further, treatment with increased concentration of insulin, a potent physiological activator of the PI3K/Akt pathway, rescued the normal level of expression of PPARγ, the master regulator of adipogenesis, and overcame the restraining effect of menadione on the differentiation capacity of 3T3-L1 preadipocytes. Our study reveals novel antiadipogenic action for menadione, which is, at least in part, mediated by the PI3K/Akt pathway signaling and raises its potential as a therapeutic agent in the treatment or prevention of adiposity.
Sujet(s)
Adipogenèse/effets des médicaments et des substances chimiques , Ménadione/pharmacologie , Cellules 3T3-L1 , Animaux , Différenciation cellulaire/effets des médicaments et des substances chimiques , Expression des gènes/effets des médicaments et des substances chimiques , Peroxydation lipidique/effets des médicaments et des substances chimiques , Souris , Stress oxydatif/effets des médicaments et des substances chimiques , Phosphatidylinositol 3-kinases/métabolisme , Protéines proto-oncogènes c-akt/métabolisme , Espèces réactives de l'oxygène/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Triglycéride/métabolismeRÉSUMÉ
The increasing impact of obesity on global human health intensifies the importance of studies focusing on agents interfering with the metabolism and remodeling not only of the white adipose tissue (WAT) but also of the liver. In the present study, we have addressed the impact of n-3 PUFA in adipose cells' proliferation and adipogenesis, as well as in the hepatic lipid profile and morphology. Mice were induced to obesity by the consumption of a high-fat diet (HFD) for 16 weeks. At the 9th week, the treatment with fish oil (FO) was initiated and maintained until the end of the period. The FO treatment reduced the animals' body mass, plasma lipids, glucose, plasma transaminases, liver mass, triacylglycerol, and cholesterol liver content when compared to animals consuming only HFD. FO also decreased the inguinal (ing) WAT mass, reduced adipocyte volume, increased adipose cellularity (hyperplasia), and increased the proliferation of adipose-derived stromal cells (AdSCs) which corroborates the increment in the proliferation of 3T3-L1 pre-adipocytes or AdSCs treated in vitro with n-3 PUFA. After submitting the in vitro treated (n-3 PUFA) cells, 3T3-L1 and AdSCs, to an adipogenic cocktail, there was an increase in the mRNA expression of adipogenic transcriptional factors and other late adipocyte markers, as well as an increase in lipid accumulation when compared to not treated cells. Finally, the expression of browning-related genes was also higher in the n-3 PUFA treated group. We conclude that n-3 PUFA exerts an attenuating effect on body mass, dyslipidemia, and hepatic steatosis induced by HFD. FO treatment led to decreasing adiposity and adipocyte hypertrophy in ingWAT while increasing hyperplasia. Data suggest that FO treatment might induce recruitment (by increased proliferation and differentiation) of new adipocytes (white and/or beige) to the ingWAT, which is fundamental for the healthy expansion of WAT.
Sujet(s)
Adipogenèse/effets des médicaments et des substances chimiques , Acides gras omega-3/pharmacologie , Huiles de poisson/pharmacologie , Stéatose hépatique non alcoolique/prévention et contrôle , Obésité/thérapie , Cellules 3T3-L1 , Adipocytes/effets des médicaments et des substances chimiques , Tissu adipeux blanc/effets des médicaments et des substances chimiques , Adiposité/effets des médicaments et des substances chimiques , Animaux , Différenciation cellulaire/effets des médicaments et des substances chimiques , Prolifération cellulaire/effets des médicaments et des substances chimiques , Alimentation riche en graisse , Mâle , Souris , Souris de lignée C57BL , Stéatose hépatique non alcoolique/étiologie , Obésité/complicationsRÉSUMÉ
The objective was to evaluate the mechanisms of digested total proteins (DTP), albumin, glutelin, and pure peptides from chia seed (Salvia hispanica L.) to prevent adipogenesis and its associated inflammation in 3T3-L1 adipocytes. Preadipocytes (3T3-L1) were treated during differentiation with either DTP or digested albumin or glutelin (1 mg/mL) or pure peptides NSPGPHDVALDQ and RMVLPEYELLYE (100 µM). Differentiated adipocytes also received DTP, digested albumin or glutelin (1 mg/mL), before (prevention) or after (inhibition) induced inflammation by addition of conditioned medium (CM) from inflamed macrophages. All treatments prevented adipogenesis, reducing more than 50% the expression of PPARγ and to a lesser extent lipoprotein lipase (LPL), fatty acid synthase (FAS), sterol regulatory element-binding protein 1 (SREBP1), lipase activity and triglycerides. Inflammation induced by CM was reduced mainly during prevention, while DTP decreased expression of NF-κB (-48.4%), inducible nitric oxide synthase (iNOS) (-46.2%) and COX-2 (-64.5%), p < 0.05. Secretions of nitric oxide, PGE2 and TNFα were reduced by all treatments, p < 0.05. DTP reduced expressions of iNOS (-52.1%) and COX-2 (-66.4%). Furthermore, digested samples and pure peptides prevented adipogenesis by modulating PPARγ and additionally, preventing and even inhibiting inflammation in adipocytes by inhibition of PPARγ and NF-κB expression. These results highlight the effectiveness of digested total proteins and peptides from chia seed against adipogenesis complications in vitro.
Sujet(s)
Adipocytes/physiologie , Adipogenèse/effets des médicaments et des substances chimiques , Inflammation/prévention et contrôle , Peptides/pharmacologie , Protéines végétales/pharmacologie , Salvia/composition chimique , Graines/composition chimique , Cellules 3T3-L1 , Adipocytes/effets des médicaments et des substances chimiques , Adipocytes/immunologie , Albumines/pharmacologie , Animaux , Fatty acid synthases/métabolisme , Glutens/pharmacologie , Métabolisme lipidique , Souris , Acylglycerol lipase/métabolisme , Facteur de transcription NF-kappa B/métabolisme , Récepteur PPAR gamma/métabolisme , Cellules RAW 264.7 , Protéines de stockage des graines/pharmacologie , Transduction du signal/effets des médicaments et des substances chimiquesRÉSUMÉ
The aim of this study was to differentiate canine adipose-derived mesenchymal stem cells (ADMSCs) into insulin-producing cells by using culture media with different compositions to determine the most efficient media. Stem cells isolated from the fat tissues close to the bitch uterus were distributed into 6 groups: (1) Dulbecco's modified Eagle medium (DMEM)-high glucose (HG), ß-mercaptoethanol, and nicotinamide; (2) DMEM-HG, ß-mercaptoethanol, nicotinamide, and exendin-4; (3) DMEM-HG, ß-mercaptoethanol, nicotinamide, exendin-4, B27, nonessential amino acids, and l-glutamine; (4) DMEM-HG, ß-mercaptoethanol, and nicotinamide (for the initial 8-d period), and DMEM-HG, ß-mercaptoethanol, nicotinamide, exendin-4, B27, nonessential amino acids, l-glutamine, and basic fibroblast growth factor (for the remaining 8-d period); (5) DMEM-HG and fetal bovine serum; and (6) DMEM-low glucose and fetal bovine serum (standard control group). Adipose-derived mesenchymal stem cells from groups 1 to 5 gradually became round in shape and gathered in clusters. These changes differed between the groups. In group 3, the cell clusters were apparently more in numbers and gathered as bigger aggregates. Dithizone staining showed that groups 3 and 4 were similar in terms of the mean area of each aggregate stained for insulin. However, only in group 4, the number of insulin aggregates and the total area of aggregates stained were significantly bigger than in the other groups. The mRNA expression of PDX1, BETA2, MafA, and Insulin were also confirmed in all the groups. We conclude that by manipulating the composition of the culture medium it is possible to induce canine ADMSCs into insulin-producing cells, and the 2-staged protocol that was used promoted the best differentiation.
Sujet(s)
Différenciation cellulaire , Milieux de culture/pharmacologie , Insuline/métabolisme , Cellules souches mésenchymateuses/physiologie , Adipogenèse/effets des médicaments et des substances chimiques , Adipogenèse/physiologie , Animaux , Carbazoles/composition chimique , Carbazoles/pharmacologie , Chondrogenèse/effets des médicaments et des substances chimiques , Chondrogenèse/physiologie , Milieux de culture/composition chimique , Chiens , Immunophénotypage , 2-Sulfanyl-éthanol/pharmacologie , Nicotinamide/composition chimique , Nicotinamide/pharmacologie , Ostéogenèse/effets des médicaments et des substances chimiques , Ostéogenèse/physiologieRÉSUMÉ
INTRODUCTION: The jabuticaba peel extract (JPE) contains bioactive compounds that regulate fat metabolism. Because the negative correlation between fat accumulation and bone formation in bone marrow, we hypothesized that JPE inhibits adipocyte as well as favors osteoblast differentiation of mesenchymal stromal cells (MSCs) under healthy and osteoporotic conditions, a disease that display an imbalance between adipocyte and osteoblast differentiation resulting in reduced bone mass. MATERIAL AND METHODS: To test these hypotheses, bone marrow MSCs were harvested from healthy and osteoporotic rats and cultured in adipogenic and osteogenic media with three concentrations of JPE, 0.25, 5 and 10 µg/ml, and vehicle (control). After selecting the most efficient concentrations of JPE, we used them to evaluate adipocyte and osteoblast differentiation of MSCs from both sources. RESULTS: We observed that, in general, JPE inhibited adipocyte differentiation of MSCs with more pronounced effects in cells from healthy than osteoporotic rats. In addition, JPE increased osteoblast differentiation, exhibiting a slightly higher osteogenic potential on MSCs from osteoporotic compared to healthy condition. CONCLUSION: Our results demonstrated that JPE drives MSCs to inhibit adipocyte differentiation and toward osteoblast differentiation under healthy and osteoporotic conditions. These findings pave the way for further translational studies to investigate the therapeutic possibilities of JPE in both prevention and treatment of osteoporosis.
Sujet(s)
Adipocytes/cytologie , Cellules souches mésenchymateuses/cytologie , Ostéoblastes/cytologie , Ostéoporose/anatomopathologie , Extraits de plantes/pharmacologie , Adipocytes/effets des médicaments et des substances chimiques , Adipocytes/métabolisme , Adipogenèse/effets des médicaments et des substances chimiques , Adipogenèse/physiologie , Animaux , Moelle osseuse/effets des médicaments et des substances chimiques , Moelle osseuse/métabolisme , Cellules de la moelle osseuse/effets des médicaments et des substances chimiques , Cellules de la moelle osseuse/métabolisme , Os et tissu osseux/effets des médicaments et des substances chimiques , Os et tissu osseux/anatomopathologie , Différenciation cellulaire/effets des médicaments et des substances chimiques , Cellules cultivées , Femelle , Cellules souches mésenchymateuses/effets des médicaments et des substances chimiques , Ostéoblastes/effets des médicaments et des substances chimiques , Ostéoblastes/métabolisme , Ostéogenèse/effets des médicaments et des substances chimiques , Ostéoporose/métabolisme , Ovariectomie , Rat WistarRÉSUMÉ
Osteoporosis is characterized by decreased bone mass and adipocyte accumulation within the bone marrow that inhibits osteoblast maturation, leading to a high risk of fractures. Thus, we hypothesized that osteoblasts, besides being negatively affected by interacting with adipocytes, reduce the differentiation of neighboring osteoblasts through the same mechanisms that affect osteoblasts under osteoporotic conditions. We investigated the effect of osteoporosis on osteoblast differentiation and the effect of the conditioned medium of osteoblasts cocultured with adipocytes on the differentiation of other osteoblasts. Osteoporosis was induced by orchiectomy in rats and bone marrow mesenchymal stromal cells (MSCs) were differentiated into osteoblasts. Also, the bone marrow and adipose tissue MSCs were obtained from healthy rats and differentiated into osteoblasts and adipocytes, respectively. Messenger RNA expression, in situ alkaline phosphatase activity, and mineralization confirmed the inhibitory effect of osteoporosis on osteoblast differentiation. This harmful effect was mimicked by the in vitro model using the conditioned medium and it was demonstrated that osteoblasts keep the memory of the negative impact of interacting with adipocytes, revealing an unknown mechanism relevant to the osteoporotic bone loss. Finally, we showed the involvement of acetyl-histone 3 (AcH3) in bone homeostasis as its reduction induced by osteoporosis and conditioned medium impaired osteoblast differentiation. The AcH3 involvement was proved by treating osteoblasts with Trichostatin A that recovered the AcH3 expression and osteoblast differentiation capacity in both situations. Together, our findings indicated that AcH3 might be a target for future studies focused on epigenetic-based therapies to treat bone diseases.
Sujet(s)
Adipocytes/métabolisme , Différenciation cellulaire , Régulation négative , Histone/métabolisme , Ostéoblastes/métabolisme , Ostéoporose/anatomopathologie , Acétylation/effets des médicaments et des substances chimiques , Adipocytes/effets des médicaments et des substances chimiques , Adipogenèse/effets des médicaments et des substances chimiques , Animaux , Différenciation cellulaire/effets des médicaments et des substances chimiques , Techniques de coculture , Milieux de culture conditionnés/pharmacologie , Régulation négative/effets des médicaments et des substances chimiques , Mâle , Modèles biologiques , Ostéoblastes/effets des médicaments et des substances chimiques , Ostéogenèse/effets des médicaments et des substances chimiques , Ostéoporose/métabolisme , Rat WistarRÉSUMÉ
AIM: Dexamethasone (DXM) is a synthetic glucocorticoid whose effects in early and terminal adipogenesis have been addressed. In this study, we evaluated if DXM affects adipocyte precursor cells (APCs), priming them for further adipogenic differentiation. For this purpose, we analyzed APCs number and competency after DXM treatment. MATERIALS AND METHODS: Adult male rats were injected for 2 or 7â¯days with either DXM (30⯵g/kg of weight, sc.) or vehicle. Stromal vascular fraction (SVF) cells from retroperitoneal adipose tissue (RPAT) were isolated to quantify APCs by flow cytometry (CD34+/CD45-/CD31-). Also, expression of competency markers (PPARγ2 and Zfp423) was assessed. Additionally, SVF cells from control rats were incubated with DXM (0.25⯵M) alone or combined with a mineralocorticoid receptor (MR) antagonist (Spironolactone 10⯵M) and/or a glucocorticoid receptor (GR) antagonist (RU486 1⯵M) to assess APCs competency and adipocyte differentiation. KEY FINDINGS: APCs from 2â¯days DXM-treated rats showed increased expression of PPARγ2 and Zfp423 (competency markers), but did not affect APCs percentage by FACS analysis (CD34+/CD45-/CD31-). Additionally, we found that DXM treatment in SVF also increased APCs competency in vitro, predisposing APCs to further adipocyte differentiation. These effects on APCs were abrogated only when both, MR and GR, were blocked. SIGNIFICANCE: Overall, our results suggest that DXM primes APCs for differentiation mainly by enhancing Zfp423 and PPARγ2 expressions. Also, we showed that the inhibition of MR and GR was necessary for the complete abolishment of DXM effects.
Sujet(s)
Adipocytes/cytologie , Adipogenèse , Dexaméthasone/pharmacologie , Cellules souches/cytologie , Adipocytes/effets des médicaments et des substances chimiques , Adipocytes/métabolisme , Adipogenèse/effets des médicaments et des substances chimiques , Adipogenèse/génétique , Tissu adipeux/cytologie , Animaux , Marqueurs biologiques/métabolisme , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Mâle , Souris , Récepteur PPAR gamma/génétique , Récepteur PPAR gamma/métabolisme , Rat Sprague-Dawley , Récepteurs aux glucocorticoïdes/métabolisme , Récepteurs des minéralocorticoïdes/métabolisme , Espace rétropéritonéal , Cellules souches/effets des médicaments et des substances chimiques , Cellules souches/métabolisme , Facteurs de transcription/métabolismeRÉSUMÉ
BACKGROUND: Bushenhuoxue formula (BSHXF) has shown excellent clinical effects on the treatment of osteoporosis in China. The aim of this study is to determine the anti-osteoporosis effects and precise molecular mechanisms of BSHXF on mouse models. METHODS: Ten-week-old female C57BL/6 J mice were subjected to ovariectomy and provided a daily treatment of BSHXF. At 8 weeks post-surgery, the femurs were harvested for tissue analyses including µCT, histology, qRT-PCR and immunohistochemical (IHC) staining of ß-catenin, ALP and FABP4. To investigate the role of ß-catenin in the anti-osteoporosis effects of BSHXF, relative experiments mentioned above were performed in ß-catenin conditional knockout mice. RESULTS: Ovariectomized (OVX) mice presented severe bone loss and excessive fat accumulation in the chondro-osseous junction underneath the growth plate, with decreased expression of ALP and increased expression of FABP4. BSHXF significantly recovered the OVX-induced abnormal osteogenesis and adipogenesis with the activation of ß-catenin in growth plate chondrocytes. Further, we generated growth plate chondrocyte-specific ß-catenin knockout (ß-cateninGli1ER) mice that exhibited bone loss and fat accumulation in the chondro-osseous junction, similar to the OVX mice. However, BSHXF failed to rescue the osteoporosis-like phenotype in ß-cateninGli1ER mice, indicating the anti-osteoporosis effects of BSHXF act mainly through ß-catenin signaling. No significant restoration of ALP and FABP4 was observed in ß-cateninGli1ER mice after the treatment of BSHXF. CONCLUSIONS: BSHXF attenuates osteoporosis by promoting osteogenic differentiation of growth plate chondrocytes mainly in ß-catenin-dependent manner. BSHXF is considered as a new candidate for the treatment of osteoporosis.
Sujet(s)
Chondrocytes/effets des médicaments et des substances chimiques , Médicaments issus de plantes chinoises/pharmacologie , Ostéogenèse/effets des médicaments et des substances chimiques , Ostéoporose/traitement médicamenteux , Adipogenèse/effets des médicaments et des substances chimiques , Animaux , Différenciation cellulaire/effets des médicaments et des substances chimiques , Chondrocytes/cytologie , Femelle , Lame épiphysaire/métabolisme , Souris , Souris de lignée C57BL , Souris knockout , Ostéoporose/anatomopathologie , Ovariectomie , Voie de signalisation Wnt/effets des médicaments et des substances chimiques , bêta-Caténine/génétique , bêta-Caténine/métabolismeRÉSUMÉ
An impaired capacity of adipose tissue expansion leads to adipocyte hypertrophy, inflammation and insulin resistance (IR) under positive energy balance. We previously showed that a grape pomace extract, rich in flavonoids including quercetin (Q), attenuates adipose hypertrophy. This study investigated whether dietary Q supplementation promotes adipogenesis in the epididymal white adipose tissue (eWAT) of rats consuming a high-fat diet, characterizing key adipogenic regulators in 3T3-L1 pre-adipocytes. Consumption of a high-fat diet for 6 weeks caused IR, increased plasma TNFα concentrations, eWAT weight, adipocyte size and the eWAT/brown adipose tissue (BAT) ratio. These changes were accompanied by decreased levels of proteins involved in angiogenesis, VEGF-A and its receptor 2 (VEGF-R2), and of two central adipogenic regulators, i.e. PPARγ and C/EBPα, and proteins involved in mature adipocyte formation, i.e. fatty acid synthase (FAS) and adiponectin. Q significantly reduced adipocyte size and enhanced angiogenesis and adipogenesis without changes in eWAT weight and attenuated systemic IR and inflammation. In addition, high-fat diet consumption increased eWAT hypoxia inducible factor-1 alpha (HIF-1α) levels and those of proteins involved in adipose inflammation (TLR-4, CD68, MCP-1, JNK) and activation of endoplasmic reticulum (ER) stress, i.e. ATF-6 and XBP-1. Q mitigated all these events. Q and quercetin 3-glucoronide prevented TNFα-mediated downregulation of adipogenesis during 3T3-L1 pre-adipocytes early differentiation. Together, Q capacity to promote a healthy adipose expansion enhancing angiogenesis and adipogenesis may contribute to reduced adipose hypertrophy, inflammation and IR. Consumption of diets rich in Q could be useful to counteract the adverse effects of high-fat diet-induced adipose dysfunction.
Sujet(s)
Adipogenèse/effets des médicaments et des substances chimiques , Tissu adipeux blanc/anatomopathologie , Antioxydants/pharmacologie , Quercétine/pharmacologie , Cellules 3T3-L1 , Adipocytes/effets des médicaments et des substances chimiques , Adipocytes/métabolisme , Tissu adipeux brun/métabolisme , Tissu adipeux blanc/métabolisme , Animaux , Antioxydants/administration et posologie , Poids/effets des médicaments et des substances chimiques , Alimentation riche en graisse/effets indésirables , Hypertrophie/traitement médicamenteux , Hypertrophie/métabolisme , Sous-unité alpha du facteur-1 induit par l'hypoxie/métabolisme , Inflammation/métabolisme , Insulinorésistance , Mâle , Souris , Obésité/métabolisme , Quercétine/administration et posologie , Quercétine/analogues et dérivés , Rats , Rat Sprague-Dawley , Facteur de nécrose tumorale alpha/sang , Facteur de nécrose tumorale alpha/métabolismeRÉSUMÉ
Previous research suggests that omega-3 fatty acids from animal origin may promote the browning of subcutaneous white adipose tissue. We evaluated if supplementation with a plant oil (chia, Salvia hispanica L.) rich in alpha-linolenic fatty acid (C18:3; ω-3) would promote browning and improve glucose metabolism in animals subjected to an obesogenic diet. Swiss male mice (n = 28) were divided into 4 groups: C: control diet; H: high-fat diet; HC: animals in the H group supplemented with chia oil after reaching obesity; HCW: animals fed since weaning on a high-fat diet supplemented with chia oil. Glucose tolerance, inflammatory markers, and expression of genes and proteins involved in the browning process were examined. When supplemented since weaning, chia oil improved glucose metabolism and promoted the browning process and a healthier phenotype. Results of this study suggested that chia oil has potential to protect against the development of obesity-related diseases.
Sujet(s)
Tissu adipeux blanc/effets des médicaments et des substances chimiques , Transdifférenciation cellulaire/effets des médicaments et des substances chimiques , Alimentation riche en graisse , Obésité/physiopathologie , Huiles végétales/pharmacologie , Salvia/composition chimique , Adipocytes blancs/effets des médicaments et des substances chimiques , Adipocytes blancs/physiologie , Adipogenèse/effets des médicaments et des substances chimiques , Adipogenèse/génétique , Tissu adipeux blanc/physiologie , Animaux , Glycémie/effets des médicaments et des substances chimiques , Glycémie/métabolisme , Compléments alimentaires , Leptine/sang , Acides linoléniques/pharmacologie , Mâle , Souris , Souris obèse , Obésité/diétothérapie , Obésité/étiologie , Obésité/métabolisme , Huiles végétales/isolement et purificationRÉSUMÉ
BACKGROUND: Obesity is a major public health concern worldwide. A sedentary life and a nutritional transition to processed foods and high-calorie diets are contributing factors to obesity. The demand for nutraceutical foods, such as herbal weight-loss products, which offer the potential to counteract obesity, has consequently increased. We hypothesised that Opuntia cladodes consumption could assist weight management in an obesity prevention context. METHODS: This study was designed to explore the anti-adipogenic effects of lyophilised Opuntia cladode powders (OCP) in an in vitro cellular model for adipocyte differentiation and an in vivo high-fat-diet (HFD)-induced obesity rat model. Two OCP were tested, one from wild species O. streptacantha and the second from the most known species O. ficus-indica. RESULTS: Pre-adipocytes 3 T3-F442A were treated by OCP during the differentiation process by insulin. OCP treatment impaired the differentiation in adipocytes, as supported by the decreased triglyceride content and a low glucose uptake, which remained comparable to that observed in undifferentiated controls, suggesting that an anti-adipogenic effect was exerted by OCP. Sprague-Dawley rats were fed with a normal or HFD, supplemented or not with OCP for 8 weeks. OCP treatment slightly reduced body weight gain, liver and abdominal fat weights, improved some obesity-related metabolic parameters and increased triglyceride excretion in the faeces. Taken together, these results showed that OCP might contribute to reduce adipogenesis and fat storage in a HFD context, notably by promoting the faecal excretion of fats. CONCLUSIONS: Opuntia cladodes may be used as a dietary supplement or potential therapeutic agent in diet-based therapies for weight management to prevent obesity.
Sujet(s)
Adipocytes/effets des médicaments et des substances chimiques , Adipogenèse/effets des médicaments et des substances chimiques , Compléments alimentaires , Fèces/composition chimique , Obésité/traitement médicamenteux , Opuntia , Animaux , Poids/effets des médicaments et des substances chimiques , Différenciation cellulaire/effets des médicaments et des substances chimiques , Alimentation riche en graisse , Glucose/métabolisme , Mâle , Mexique , Poudres , Rats , Rat Sprague-Dawley , Triglycéride/métabolismeRÉSUMÉ
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have benefits in the metabolism of adipose tissue. However, its contribution to the adipogenesis is not entirely elucidated. The study aimed to evaluate the effects of EPA and DHA on adipogenesis, especially in the PPARγ (peroxisome proliferator-activated receptor-gamma) and Cidec (cell death-inducing DFFA-like effector c) pathway. Twenty-four hours after confluence, 3T3-L1 adipocytes were treated with EPA (100 µM), DHA (50µM) and EPA (100µM) + DHA (50µM) and at the end of differentiation (day 11) the cells were collected for analysis. Cell viability analysis indicated that the concentrations used for EPA and DHA did not cause cytotoxicity in cultured 3T3l1 adipocytes. The treatments have lessened the triacylglycerol accumulation in the adipocyte cytoplasm that, compared to the control group, were EPA-32%, DHA-38%, EPA + DHA -24%. The double-labeling immunofluorescence showed a signal attenuation of protein expressions of PPARγ, CIDEC, and SREBP-1c (sterol regulatory element-binding protein). EPA and DHA had a significant impact on the expression of cleaved CASPASE 3, which increases cell apoptosis and gene expressions of Pparγ and Cidec in the treated groups. Also, there was a reduction of C/ebpα (CCAAT/enhancer-binding protein alpha), Cd36 (cluster differentiation 36), and Foxo1 (forkhead box O). In conclusion, the study determined the ability of both EPA and DHA, alone or combined, in the adipogenesis modulation in cultured 3T3-L1 adipocytes, affecting the cell differentiation, maturation, and consequently, reducing adipogenesis via PPARγ-CIDEC suppression.